The mechanisms underlying phenacetin-induced toxicity and carcinogenicity are not clear. In particular, it is not known whether these effects are mediated by metabolic activation of the drug. CYP1A2 is known to metabolize phenacetin in vitro. To determine the role of this enzyme in vivo, the toxicity and carcinogenicity of phenacetin was examined in Cyp1a2-null mice (that lack CYP1A2). Six-to 8-week-old wild type (؉/؉) or null (-/-) mice were fed either a control diet, or one containing 1.25% phenacetin, ad libitum for up to 67 weeks. Representative groups of mice were examined for phenacetin-induced toxicity and carcinogenicity after 36, 48, 58, or 67 weeks of feeding. Consistent with the known role of CYP1A2 in phenacetin metabolism, plasma levels of phenacetin were higher and acetaminophen levels lower in the (-/-) mice fed phenacetin compared to phenacetin-fed (؉/؉) controls. Weight gain was significantly depressed in both groups of phenacetin-fed mice after 4 weeks of feeding, and continued to be lower for the remainder of the experiment, compared to controls. Hepatomegaly and splenomegaly were more severe in (-/-) mice but present in both genotypes fed phenacetin at all time points assessed. Histological analysis of liver, kidney, spleen, and urogenital tract also revealed a differential response in the (-/-) mice fed phenacetin compared to (؉/؉) mice fed the same diet. Further, mortality was the most severe in the (-/-) mice fed phenacetin than in all other groups. Despite significant toxicity in (-/-) mice fed phenacetin, only one renal carcinoma was found among them.
Phenacetin is an analgesic that was commonly used between 1970 and 1980, before it was found to cause renal and urinary tract tumors in experimental animal models. (Johansson, 1981; Johansson and Angervall, 1976; Johansson et al., 1974; Johansson and Wahlqvist, 1977; Nakanishi et al., 1982) . Epidemiological evidence in humans also suggested an association of analgesic consumption with urinary tract hyperplasia and/or cancers (Dubach et al., 1983 (Dubach et al., , 1991 . Long-term feeding studies in animals have demonstrated that phenacetin toxicity and carcinogenicity specifically affects both renal and urinary tract epithelium (Nakanishi, et al., 1982) . In addition to its known effects on kidney and the urogenital tract, phenacetin also causes methemoglobinemia (Shahidi, 1968; Shahidi and Hemaidan, 1969) . The mechanisms underlying phenacetin-induced toxicity and carcinogenicity are not known. In particular, it is not clear whether phenacetin or a metabolite underlie its toxicity and carcinogenicity.
The first step in phenacetin metabolism is O-deethylation by cytochrome P450 1A2 (CYP1A2) resulting in the formation of acetaminophen. Further metabolism results in conjugation with glucuronide, sulfate, or glutathione to form products that are ultimately excreted in urine. Potentially reactive intermediates can also result from either phenacetin or acetaminophen metabolism by enzymes other than CYP1A2 (Hinson, 1983; Veronese et al., 1985) . It is these reactive intermediates that have been postulated to account for the toxicity and carcinogenicity of phenacetin, in particular, quinone metabolites resulting from CYP2E1 metabolism of acetaminophen (Hinson, 1983; Veronese, et al., 1985) . CYP1A2 metabolism of phenacetin has been implicated in altering the toxic effects of this compound (Nakayama and Masuda, 1985; Sesardic et al., 1990) . While in vitro experiments have suggested that CYP1A2 metabolism of phenacetin initiates detoxification of this drug, the role of this enzyme in an in vivo model has not been investigated. In this study, the hypothesis that phenacetin is more toxic and carcinogenic in the Cyp1a2-null mouse was tested.
MATERIALS AND METHODS
Experimental design. The construction and preliminary phenotypical characterization of the Cyp1a2-null mice used in this work have been previously described (Pineau et al., 1995) . Heterozygous male and female mice, F 4 generation from the original colony of mixed genetic background (Sv/ 129ϫC57BL/6N), were bred to obtain wild-type (ϩ/ϩ) or Cyp1a2-null (-/-) mice. The homozygous (ϩ/ϩ) and (-/-) mice used in this work were of similar mixed genetic background, since they were derived from the same founder mice. Male mice, homozygous, (ϩ/ϩ) or (-/-), and 6 -8 weeks-of-age, were housed in a temperature-and light-controlled environment. Phenacetin was purchased commercially (Sigma, St. Louis, MO) and pelleted mouse chow was made containing either 0.0 or 1.25% phenacetin (Bioserv, Piscataway, NJ). This concentration was used because chronic feeding of phenacetin at this level has been shown to be carcinogenic in mice (Nakanishi, et al., 1982) . Mice were fed ad libitum and body weights were measured weekly. Animal care was provided in accordance with procedures outlined in the Guide for the Care and Use of Laboratory Animals (National Research Council [NRC], 1996) under an animal study proposal approved by the NCI, DBS Animal Care and Use Committee.
Necropsy. Representative animals from each treatment group (4 -9 mice/group) were euthanized by overexposure to carbon dioxide after 36, 48, 58, or 67 weeks of feeding the respective diet. Blood was collected by cardiac puncture and plasma obtained by standard procedures. Tissues were examined for gross lesions, weighed, placed in 10% phosphate-buffered formalin (PBF), and embedded in paraffin. Sections were prepared at 5 m and stained with hematoxylin and eosin. Selected sections were stained for iron (Prussian blue).
Pathology. Pathological findings were recorded using the following qualitative scoring criteria: none (-), minimal (ϩ/-), slight (ϩ), moderate (ϩϩ), and marked (ϩϩϩ). Grades of non-proliferative lesions for each group were calculated by the following formula: Grade, (1 ϫ no. (ϩ/-) animals) ϩ (2 ϫ no. (ϩ) animals) ϩ (3 ϫ no. (ϩϩ) animals) ϩ (4 ϫ no. (ϩϩϩ) animals)/no. animals. Histological evaluations were performed by 2 pathologists with and without knowledge of the treatment groups to verify the findings.
Plasma phenacetin and acetaminophen analysis. One hundred fifty L of plasma was diluted with 5 mL of acetone to precipitate protein. Samples were lyophilized under nitrogen and then redissolved in 50 L of mobile phase. HPLC was performed using a Hewlett-Packard (HP) model HP1050 liquid chromotography system equipped with an HP model 1050 autosampler, a ternary solvent delivery system, and a multiple-wavelength or dioarray detector controlled by the HPLC2D or 3D ChemStation software. For separation of phenacetin and its metabolites, a 20/20 ODS column (4.6 ϫ 250 mm, 5 m) was used with a mobile phase of acetonitrile/water (10:90 v/v, 0.05% acetic acid) for 8 min and followed by a linear gradient to acetonitrile/water (50:50 v/v, 0.05% acetic acid) in 10 min. The metabolite and substrate were detected at UV 250 nm (Mineshita et al., 1986) . Concentration was calculated by integrating AUC values from either standard (phenacetin or acetaminophen) with AUC values for respective samples.
Statistical analysis. Differences between groups for body and tissue weights were determined by 2-way ANOVA and Scheffe's F-test (Statview 4.02, Abacus Concepts, Berkeley, CA). Differences between genotypes for plasma levels of phenacetin and acetaminophen were determined by an unpaired StudentЈs t-test (Statview 4.02, Abacus Concepts, Berkeley, CA). For mortality frequency, differences between groups were determined by Chi-square analysis (Statview 4.02, Abacus Concepts, Berkeley, CA). Histological data for the incidence of particular lesions were analyzed for differences between groups with the Fisher Exact Test (JMP, SAS Institute, Cary, NC).
RESULTS

Plasma Analysis
To determine whether phenacetin metabolism differed between (ϩ/ϩ) and (-/-) mice, plasma levels of the drug were analyzed. After 36 -48 weeks of treatment the concentration of phenacetin in (-/-) mice fed phenacetin was significantly higher compared to phenacetin-fed (ϩ/ϩ) mice. In addition, mean plasma levels of acetaminophen and acetaminophen conjugates were significantly lower in phenacetin-fed (-/-) mice compared to (ϩ/ϩ) mice fed phenacetin (Fig. 1) . The low level of acetaminophen found in (-/-) mice fed phenacetin could be due to metabolism of phenacetin by CYP1A1 (Sesardic, et al., 1990) .
Body Weight
Mean body weights were significantly lower in both CYP1A2 genotypes fed 1.25% phenacetin compared to controls after 18 weeks of feeding and this trend continued for the duration of the experiment (Fig. 2) . There was no difference in body weight observed between control (ϩ/ϩ) and (-/-) throughout the experiment.
Mortality
In the control (ϩ/ϩ) group, phenacetin (ϩ/ϩ) group, and control (-/-) group, mortality was not statistically different ( Fig.  3) . In contrast, in the (-/-) group fed phenacetin, significantly more mice died over the course of the experiment (33%) compared to the other groups. Histologically, these mice had severe, multiple organ toxic lesions described below.
FIG. 1.
Plasma levels of phenacetin and acetaminophen (and acetaminophen conjugates) in wild-type (ϩ/ϩ) or Cyp1a2-null (-/-) mice fed a 1.25% phenacetin diet for 36 -48 weeks. Plasma was analyzed for phenacetin or acetaminophen and acetaminophen conjugates (APAP) by HPLC. Phenacetin and acetaminophen were undetectable in plasma from control mice from both genotypes. Values represent the mean Ϯ SD. *Significantly different from wild-type; p Ͻ 0.05.
Organ Weights
After 36 weeks of feeding, both (ϩ/ϩ) and (-/-) mice fed phenacetin exhibited signs of hepatotoxicity as evidenced by the mean relative liver weight, which was significantly higher in these groups compared to untreated controls (Table 1 ). In contrast, splenomegaly observed in (-/-) mice fed phenacetin for 36 weeks was significantly greater compared to (ϩ/ϩ) mice fed phenacetin (Table 1 ). After 48 weeks of feeding, hepatomegaly and splenomegaly were present in both Cyp1a2 genotypes fed phenacetin compared to controls, but there was no difference in the extent of these effects between genotypes (Table 1) . After 58 weeks and 67 weeks of feeding, the increase in relative liver weight and spleen weight was still observed in the (ϩ/ϩ) mice fed phenacetin compared to controls. However, compared to (ϩ/ϩ) mice fed phenacetin at these timepoints, hepatomegaly and splenomegaly was significantly greater in the (-/-) mice fed phenacetin (Table 1) .
Toxic Lesions
Fibrosis and inflammatory cell infiltration in the submucosa of the urinary bladder (Fig. 4a, 4b ) was noted in both (ϩ/ϩ) and (-/-) mice fed phenacetin at all time points examined (Table 2 ). There were no differences in the incidence or in the grade of severity in these findings between these 2 groups. Focal hyperplasia of the transitional epithelium and pigmentation in the submucosa of the urinary bladder were observed in a few animals in both (ϩ/ϩ) and (-/-) mice fed phenacetin. None of these effects was observed in respective control groups fed control diets. No bladder tumors were found in any mice.
Dilation of the pelvis, basophilic renal tubules, infarcts, calcification of the renal papilla (renal papillary necrosis), and pigmentation of the renal tubules were observed in almost all animals in both (ϩ/ϩ) and (-/-) mice fed phenacetin, at 48, 58, and 67 weeks (Figs. 4c, 4d) . The grade of severity in the (-/-) mice fed phenacetin were more pronounced compared to the (ϩ/ϩ) mice fed phenacetin after 58 and 67 weeks (Table 2) .
Hepatocyte nuclear pleomorphism, hypertrophy, glycogen depletion, and pigmentation of the Kupffer cells (Figs. 4e, 4f) were observed in almost all (ϩ/ϩ) and (-/-) mice fed phenacetin at all time points examined. However, the grade of severity was more pronounced in the (-/-) mice compared to (ϩ/ϩ) mice (Table 2 ). Minimal to slight hepatocyte hypertrophy was sporadically observed in control (ϩ/ϩ) and (-/-) mice. Extramedullary hematopoiesis in the liver was observed only in (-/-) mice fed phenacetin, after 36, 48, and 58 weeks. Hepatocyte intranuclear inclusion bodies were found in both (ϩ/ϩ) and (-/-) mice fed phenacetin after 67 weeks of treatment.
Pigmentation and extramedullary hematopoiesis in the spleen were observed in animals from all groups. However, these changes were more prominent in the (ϩ/ϩ) and (-/-) mice fed phenacetin compared to the control groups. Only in the spleens of (-/-) mice fed phenacetin, osseous metaplasia with bone marrow formation was observed in the red pulp of 2, 3, 1, and 1 mice after 36, 48, 58, and 67 weeks, respectively (Figs. 4g, 4h; Table 2 ). While the incidence of splenic osseous metaplasia in (-/-) mice fed phenacetin was not statistically different from other groups, this lesion is extremely rare and was found only in this group. We did not analyze blood from phenacetin-treated mice for anemia, but splenic lesions suggested the presence of anemia at all time points assessed.
Tumors and other proliferative lesions were also found in the mice of different groups (Table 3) . Lymphomas originated most commonly in Peyer's patches of the small intestine or the lymph nodes. The incidence was lowest in (-/-) treated mice (0%) but similar among the other treated groups (33-44%) at 67 weeks. Pulmonary adenomas were found only in (-/-) mice fed phenacetin after 48 weeks but were present in similar incidence in both phenacetin-fed groups after 67 weeks. An hepatocellular adenoma was observed in one control (-/-) male   FIG. 3 . Mortality in wild-type (ϩ/ϩ) or Cyp1a2-null (-/-) mice fed either control or 1.25% phenacetin diet. Percentages represent the number of mice that died over the course of the experiment (up to 67 weeks). Control (ϩ/ϩ) mice died after 8, 30, 32 and 41 weeks; phenacetin (ϩ/ϩ) mouse died after 20 weeks; control (-/-) mice died after 19 and 34 weeks; phenacetin (-/-) mice died after 7, 13, 20, 24, 24, 31, 44, 45, 46, 50 and 50 weeks. *Significantly different from (ϩ/ϩ) control, (-/-) control and (ϩ/ϩ) phenacetin; p Ͻ 0.05.
FIG. 2.
Effect of phenacetin feeding on body weight in wild-type (ϩ/ϩ) or Cyp1a2-null (-/-) mice. Mice were fed either control or 1.25% phenacetin diet ad libitum. Values represent the mean Ϯ SD. *Significant differences at 18, 36, 48, 58, and 67 weeks were (ϩ/ϩ) phenacetin and (-/-) phenacetin versus (ϩ/ϩ) control and (-/-) control; p Ͻ 0.05. at 58 weeks. At 67 weeks, hepatocellular adenomas were observed in 1, 5, and 1 mice in the (ϩ/ϩ) phenacetin, (-/-) control and (-/-) phenacetin groups, respectively. Interestingly, one (-/-) mouse fed phenacetin had a small renal carcinoma, but all other mice examined had no signs of this lesion. An unusual gastric proliferative and metaplastic lesion (eosinophilic metaplasia) was found only in control (-/-) mice (Table  3) . It was observed in 12/22 (-/-) control mice but only in 1/22 (-/-) mice fed phenacetin.
DISCUSSION
Since CYP1A2 catalyzes O-deethylation of phenacetin, and administration of phenacetin is known to cause toxicity and carcinogenesis, the effect of long-term phenacetin feeding was evaluated in Cyp1a2-null mice. Cyp1a2-null mice fed phenacetin showed significant signs of toxicity that were differentially present, when compared to (ϩ/ϩ) mice fed phenacetin. The most apparent indication of chronic chemical toxicity is loss of body weight. The extent of body weight depression in (-/-) and (ϩ/ϩ) mice fed phenacetin was similar compared to controls. It should be pointed out that the depression in body weight may be due to reduced food intake, which was not measured in this work. However, hepatomegaly and splenomegaly were exacerbated in the (-/-) mice fed phenacetin compared to (ϩ/ϩ) fed the same diet. Toxic lesions in kidney, liver, and spleen in (-/-) mice fed phenacetin were also more severe than in (ϩ/ϩ) mice fed phenacetin. In addition, mortality rates were significantly greater over the course of the experiment in the phenacetin-fed (-/-) mice compared to all other groups. Since the toxic effects of phenacetin were either absent or less severe in (ϩ/ϩ) mice than in (-/-) mice, these results suggest that metabolism of phenacetin by CYP1A2 results in a protective effect against its toxicity. This is consistent with the hypothesis that phenacetin produces more toxicity in mice lacking CYP1A2.
Lymphomas were consistently observed in both control groups and in (ϩ/ϩ) mice fed phenacetin. In contrast, lymphomas were not found in any of the (-/-) mice fed phenacetin. It is possible that the more severe toxic effects observed in tissues from (-/-) mice fed phenacetin (i.e. kidney, spleen and liver), that resulted from lack of CYP1A2, contributed to this phenomena by an undetermined mechanism. Stomach lesions were frequently observed in (-/-) control mice as well as phenacetin-fed (-/-) mice. This has not been previously reported and the mechanism underlying this effect remains to be determined. The reduction in the incidence of this lesion and lymphoma in (-/-) mice fed phenacetin may be due to a similar mechanism. Body weight depression (perhaps due to decreased food intake) is correlated with a lower incidence of tumors and related lesions (Blackwell et al., 1995) .
The unusual lesion of spleen-osseous metaplasia was found only in (-/-) mice fed phenacetin. This lesion may originate from splenic toxicity resulting from hemosiderin deposition and red pulp/trabecular tissue damage. Pulmonary adenomas were found only in (-/-) mice fed phenacetin after 48 weeks. However, the incidence of this lesion was similar after 58 weeks. Further, after 67 weeks of feeding, pulmonary adenomas were found at a higher incidence in both (ϩ/ϩ) and (-/-) mice fed phenacetin. Nevertheless, the presence of pulmonary adenomas only in the (-/-) mice, prior to when they are found in (ϩ/ϩ) mice fed phenacetin, is suggestive that metabolism of phenacetin by CYP1A2 protects against this carcinogenic effect. No bladder tumors were seen, despite the presence of severe fibrosis and mild hyperplasia. Further, no renal pelvic tumors were observed although severe renal toxicity was noted. While significant phenacetin-induced toxicity was found that was exacerbated in (-/-) mice, there was no consistently higher incidence of carcinogenesis within any group of mice, when using a similar dosing regime of phenacetin that has been reported to cause tumors in B6C3F1 mice (Nakanishi, et al., 1982) . This disparity in results may be due to strain differences. Thus, these results do not conclusively support the hypothesis that phenacetin is more carcinogenic in the Cyp1a2-null mouse.
The mechanisms underlying phenacetin-induced toxicity and carcinogenicity are not well-characterized. Phenacetin can be metabolized to 4 different compounds: (1) acetaminophen by CYP1A2, (2) phenacetin-3,4 epoxide, (3) N-hydroxyphenacetin, and (4) 2-hydroxyphenetidine. The majority of phenacetin will be converted to acetaminophen by CYP1A2. Acetaminophen is then converted to the reactive N-acetyl-pbenzoquinoneimine (NABQ), and the NABQ is further metabolized and conjugated before excretion in the urine. Given the complexity of phenacetin metabolism and the fact that some of its metabolites have extremely short half-lives, it is difficult to identify a particular compound that causes cel- lular changes resulting in toxicity or carcinogenicity. However, a number of reactive intermediates can be formed from phenacetin, including N-hydroxyphenacetin, phenacetin 3,4 epoxide, and NABQ, all of which have been implicated in contributing the toxic and carcinogenic effects of phenacetin (Veronese, et al., 1985) . APAP levels in (-/-) mice fed phenacetin were substantially lower and phenacetin levels significantly higher than similarly fed (ϩ/ϩ) mice, suggesting that the contribution of NABQ to phenacetin toxicity is less than that caused by potentially other reactive metabolites. Since phenacetin is minimally metabolized to acetaminophen in the (-/-) mice and the toxicity is exacerbated, this suggests that other phenacetin metabolites contribute to toxicity. For example, in the absence of CYP1A2-mediated conversion to acetaminophen, metabolism of phenacetin to N-hydroxyphenacetin and phenacetin-3,4 epoxide may be substantially increased, which could cause the differential response observed in toxic responses between (-/-) and (ϩ/ϩ) mice fed phenacetin. Additionally, further metabolism of N-hydroxyphenacetin could result in producing compounds that may contribute to this effect. These results indicate that metabolism of phenacetin by CYP1A2 reduces its toxicity in the liver, kidney, and spleen; tissues that are known to be affected by phenacetin administration. That CYP1A2 metabolism of phenacetin is important in reducing the toxicity is supported by the observation that plasma levels of phenacetin and acetaminophen were higher and lower respectively in (-/-) mice fed phenacetin compared to phenacetin fed (ϩ/ϩ) mice, and that (-/-) mice exhibited exacerbated toxicity and increased mortality compared to similarly treated (ϩ/ϩ) mice. This is the first report using an in-vivo model system that demonstrates a significant role of CYP1A2 metabolism in altering phenacetin toxicity. Results from this work indicate that either phenacetin or another phenacetin metabolite generated by a CYP1A2-independent pathway contributes significantly to the toxicity of phenacetin. In fact, there is evidence that metabolites of phenacetin resulting from pathways that do not require CYP1A2 may contribute to the genotoxicity of this compound (Calder et al., 1976; Mulder et al., 1984; Wirth et al., 1982) . In the absence of CYP1A2, these metabolic pathways may be enhanced since phenacetin is not metabolized to acetaminophen as efficiently. The specific role of phenacetin metabolites in mediating the toxicity of phenacetin is unclear, but clearly, CYP1A2 metabolism protects against such damage. 
